Frontlight ResearchEarly access
Taking peoplePhase 1
Study of how QL0911 moves through and acts in the body
Tests QL0911 in adults, looking at how the body handles it.
Key facts
- Who runs it
- Qilu Pharmaceutical Co. Ltd.
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 76 people, planned
- Started
- 4 Sept 2026
- Expected to end
- 20 Jun 2027
- Type of study
- Interventional
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 to study how QL0911 moves through and acts in the body. Healthy volunteers can join.
- Age
- 18 Years to 64 Years
- Sex
- All sexes can join
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Study of how QL0911 moves through and acts in the bodyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from 2025-523355-59-00, who can take part
- Record updated
- 6 July 2026